Please login to the form below

Not currently logged in
Email:
Password:

Cancer Drugs Fund

This page shows the latest Cancer Drugs Fund news and features for those working in and with pharma, biotech and healthcare.

NICE recommends Roche’s Polivy for B-cell lymphoma

NICE recommends Roche’s Polivy for B-cell lymphoma

Earlier this year, NICE initially rejected the new cancer drug, citing a lack of long-term evidence as the reason for the rejection. ... NICE said that the cost-effectiveness of the Polivy combination treatment was ‘very uncertain’, meaning it

Latest news

More from news
Approximately 53 fully matching, plus 121 partially matching documents found.

Latest Intelligence

  • 30 Women Leaders in UK Healthcare 30 Women Leaders in UK Healthcare

    A very notable victory has just been announced, with Keytruda becoming the first of the groundbreaking immunotherapy drugs to exit the Cancer Drugs Fund and secure NICE approval for first-line ... Current projects include developing antibodies for use as

  • Uncertainty, austerity and Brexit Uncertainty, austerity and Brexit

    Companies have seen repeated attempts by the Government and NHS England to prevent patients from accessing new medicines, from the controversial reforms to the Cancer Drugs Fund to the ‘run rate’

  • Opening up market access Opening up market access

    In this PME market access supplement we look at the direction of travel in France and Germany and there’s an introduction to the UK’s new-look Cancer Drugs Fund.

  • Stepping up to payer-driven market access Stepping up to payer-driven market access

    products. In the UK, for instance, NICE now regulates access to the Cancer Drugs Fund, and products will need to meet NICE thresholds in order to be reimbursed.

  • The price is right? The price is right?

    Health stakeholders should focus not on the cost of drugs but on the value they provide. ... Proposed changes to the Cancer Drugs Fund in England include provision for access at a provisional price that is considered potentially cost-effective.

More from intelligence
Approximately 2 fully matching, plus 12 partially matching documents found.

Latest appointments

  • New health ministers and re-appointments after reshuffle New health ministers and re-appointments after reshuffle

    Freeman's role is also tied into the Department for Business, Innovation and Skills and includes expanded responsibility for the Cancer Drugs Fund, NICE and MHRA, research and development, issues around ... the uptake of new drugs and med tech, and the

  • Celgene names general manager for UK and Ireland Celgene names general manager for UK and Ireland

    This is even more pertinent with the recent changes to the Cancer Drugs Fund, which I strongly hope will enable patients with myeloma and metastatic pancreatic cancer to continue to be

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
BOLDSCIENCE

We know what it takes to create brands, to start new conversations, to simply communicate complex science, to change lives…...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...

Infographics